Breaking Finance News

A statement released earlier today by Piper Jaffray about Bioverativ (OTC:BIVV) bumps the target price to $71.00

Having a price of $59.22, Bioverativ (OTC:BIVV) traded -2.24% lower on the day. With the last close up 1.65% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the same period. Bioverativ has recorded a 50-day average of $57.55 and a two hundred day average of $57.92. Volume of trade was down over the average, with 541,121 shares of BIVV changing hands under the typical 1,049,570

Stating a potential upside of 0.20%, Piper Jaffray upped the price target of Bioverativ (OTC:BIVV) to $71.00

On 09/20/2017, Argus released a statement on Bioverativ (OTC:BIVV) upped the target price from $0.00 to $64.00 that suggested an upside of 0.13%.

Performance Chart

Bioverativ (OTC:BIVV)

With a total market value of $0, Bioverativ has price-earnings ratio of 13.99 with a one year low of $40.00 and a one year high of $64.41 .

More About Bioverativ (OTC:BIVV)

Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.